CRISPR Therapeutics AG (CRSP) Stock: Price, Forecast & Analyst Target
CRISPR Therapeutics AG (CRSP) — MoonshotScore 22/100 (Weak band), calculated Nov 18, 2026. Price $39.10 (+0.44%), as of the Nov 20, 2026 trading session; market cap $3.79B.
Educational signal · not a buy or sell recommendation · How to read this
CRISPR Therapeutics AG · CRSP · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: CRSP is a gene-editing biotechnology company with a portfolio of investigational therapies for blood disorders, cancers, and rare conditions using CRISPR and Cas technology. The decisive question is whether the flagship ex vivo therapy advances to approval and market adoption before cash reserves diminish.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · CRISPR Therapeutics AG (CRSP)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, weak growth and a full valuation, though the balance sheet is only middling. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Okay; Valuation: Full; Growth Durability: Fading; Momentum: Quiet.
- quarterly revenue $1M (Q1 FY2026, quarter ended Mar 2026)
- EPS beat 0 of the last 4 reports
- Altman Z 1.77 · Piotroski F 2
Holding back: weak fundamentals, soft growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak | |
| 22 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $39.10 | |
| Change on the day | +0.44% | |
| 52-week range | $39.10–$63.45 | |
| Market capitalisation | $3.79B | — |
| Shares traded on the day | 3.32M | |
| Beta (volatility vs the S&P 500) | 1.9 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for CRISPR Therapeutics AG (CRSP): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is CRISPR Therapeutics AG (CRSP), and what does it report?
Short answer · as of
CRSP develops ex vivo and in vivo gene-edited therapies targeting hemoglobinopathies, malignancies, and rare diseases.
Research dated 2026-09-13.
The flagship ex vivo therapy modifies patients' own hematopoietic stem cells to boost fetal hemoglobin production in red blood cells for sickle cell disease and beta-thalassemia. The company pursues allogeneic CAR-T candidates and a stem cell-derived immune-evasive product for type diabetes. The income statement reflects a pre-revenue biotech model: revenues minimal, operating expenses substantial, with burn driven by clinical programs and development infrastructure.
Partnerships with Bayer, Vertex, and others provide capital infusions and potentially offset some burn, but do not materially reduce cash consumption needs. The path to profitability requires the lead program or another candidate to reach market and generate significant royalties or milestone payments.
What do the latest results show for CRISPR Therapeutics AG (CRSP)?
Short answer · as of
The most recent reported quarter, Q1 FY2026, carried revenue of $1M.
Research dated 2026-09-13.
Recent quarters show losses have tightened from prior periods, with the most recent quarter missing earnings expectations narrowly while revenue came in ahead of forecast, an unusual outcome for pre-revenue biotech. This improvement reflects operational discipline in spending and, crucially, the beginning of royalty revenue from partnership arrangements. The gross margin on limited revenue is highly positive, a signal that when scale arrives, unit economics will be favorable.
The near-term catalyst is regulatory progress on the lead program. Evidence of approval momentum or expanded partnership payments would improve burn and extend runway. Conversely, a clinical setback or partner de-emphasis would pressure the timeline and valuation.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 2 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 FY2026 | $1M | -$123M | -$1.28 (diluted) |
| Q2 FY2026 | $10M | -$91M | -$0.94 (diluted) |
What are the financial strengths and risks for CRISPR Therapeutics AG (CRSP)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13.
The company holds substantial cash and short-term investments relative to its annual burn, providing visibility into a runway that extends several years into the future even without additional capital infusions. This cash position is a major strength in a sector where many biotech firms burn through liquidity quickly. The current ratio and quick ratio are exceptionally strong, indicating no near-term solvency pressure.
However, the path to cash flow positivity depends on program success. Debt is modest and well-covered. The distress screens show warning signs in the negative net margin and return metrics, which are expected for a pre-commercial biotech but would be concerning if cash runway tightens.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 1.77 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-25.6%) — the business is not currently generating profit on shareholder capital.
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at CRISPR Therapeutics AG (CRSP)?
Short answer · as of
Current published price targets run low $52.00 · high $110.00 · consensus $72.43 · median $70.00 against a quoted price of $39.10 (as of Nov 20, 2026).
Research dated 2026-09-13.
Watch for regulatory milestone announcements on the lead program, particularly topline efficacy and safety data. The company guided that capital runway extends through multiple coming years, so focus will be on development milestones, not financing urgency. Analyst estimates for profitability remain pessimistic through the decade, reflecting the probability that revenue does not materialize if trials encounter unexpected risks.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- The newest quarter held here (Q1 FY2026) was filed May 4, 2026 — 6 months ago.
Checked against the records this page reads, on the dates shown above.
How does CRISPR Therapeutics AG compare with its peers?
Short answer
CRISPR Therapeutics AG's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Definium operates in a competitive space with multiple companies advancing mood and neurodevelopmental treatments. Differentiation rests on the specific mechanism and the trial design. The company's focus on leading programs sits against a competitive landscape including larger pharmaceutical incumbents with diversified pipelines. Scale and capitalization are asymmetric.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.17 Nov 20, 2026 | $2.92B | 97 5-pillar Nov 18, 2026 | |
| $308.89 Nov 20, 2026 | $9.15B | 96 5-pillar Nov 18, 2026 | |
| $57.52 Nov 20, 2026 | $2.94B | 95 5-pillar Nov 18, 2026 | |
| $26.36 Nov 20, 2026 | $3.33B | 89 5-pillar Nov 18, 2026 | |
| $39.91 Nov 20, 2026 | $4.37B | 84 5-pillar Nov 18, 2026 | |
| $17.58 Nov 20, 2026 | $5.04B | 83 5-pillar Nov 18, 2026 | |
| $46.53 Nov 20, 2026 | $3.42B | 72 5-pillar Nov 18, 2026 | |
| $17.59 Nov 19, 2026 | $3.04B | 68 5-pillar Nov 18, 2026 | |
| $13.61 Nov 20, 2026 | $4.78B | 67 5-pillar Nov 18, 2026 | |
| $26.02 Nov 20, 2026 | $3.35B | 66 5-pillar Nov 18, 2026 | |
| $21.73 Nov 20, 2026 | $3.68B | 62 5-pillar Nov 18, 2026 | |
| $55.39 Nov 20, 2026 | $8.77B | 51 5-pillar Nov 18, 2026 | |
| CRISPR Therapeutics AG (CRSP) — this page | $39.10 | $3.79B | 22 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $52.00 – $110.00
- Consensus target
- $72.43
- Median target
- $70.00
Consensus record · Captured .
Measured against a quoted price of $39.10 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 4, 2026
- Transactions
- 36
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 7
- Other transactions
- 29
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CRSP in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| ARK Invest | Cathie Wood | Q3 2026 | 3.20% | $556.34M | Added +6.3% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about CRISPR Therapeutics AG (CRSP)?
Common Questions About CRSP (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What is the lead ex vivo therapy?
This ex vivo gene-edited therapy modifies patients' own blood-forming stem cells to produce high levels of fetal hemoglobin, which prevents the sickling or crystallization that causes pain and organ damage in sickle cell disease and beta-thalassemia. It is the company's most advanced program and the basis of partnerships with Bayer and Vertex that provide royalty and milestone revenue. Approval and commercial launch would be transformative for CRSP's valuation and cash position. The addressable patient population is sizable but defined, so realistic expectations matter.
How long can the company operate at current burn rates?
The company has substantial cash and minimal debt, providing a runway that extends several years even without additional partnering or capital raises. The quarterly operating cash burn is in the range of hundreds of millions annualized, well below the cash on hand. However, this runway is not infinite. Acceleration of programs or increased headcount could shorten it. Conversely, additional partnership milestones or strategic capital raises could extend it indefinitely.
What are the key clinical risks?
The lead program must demonstrate durability of effect, safety over long follow-up periods, and consistent manufacturing to advance through late-stage trials. Off-target gene editing, immune responses, and manufacturing variability are known risks in the CRISPR space. Clinical trials could fail or show safety signals that limit the addressable population. The in vivo programs for liver, lung, muscle, and central nervous system disorders face additional hurdles around tissue delivery and specificity that are not yet fully solved.
Does insider activity suggest confidence in near-term progress?
Insider transactions over the recent window show sales but also grants and awards, a mix typical of pre-revenue biotech. The sales clustered around certain dates and price ranges, suggesting opportunistic trimming rather than wholesale confidence abandonment. The net of insider activity is small relative to the institution's positions, so it is not a strong signal in either direction.
What is the CRSP stock price today?
The last price recorded for CRISPR Therapeutics AG (CRSP), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CRSP price target?
The analyst consensus price target for CRISPR Therapeutics AG (CRSP), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Claude (claude-haiku-4-5) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 21 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold CRSP
Funds in our ETF coverage that list CRSP among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| ARK Innovation ETF (ARKK) | 4.73% |